Logo
x

Search

Subscribe Now

hiv-1

Merck Presents Results of Islatravir + Doravirine in P-IIb Clinical Trial for the Treatment of HIV-1 at EACS 2021

Merck Presents Results of Islatravir + Doravirine in P-IIb Clinical Trial for the Treatment of HIV-1 at EACS 2021

  • October 27, 2021
Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection

Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection

  • October 25, 2021
Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded Indication to Treat HIV-1

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded In...

  • October 19, 2021
Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

  • August 20, 2021
Gilead Reports Submission of NDA to the US FDA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

Gilead Reports Submission of NDA to the US FDA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options

  • June 29, 2021
Innovent's Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) Receive the NMPA's Approval as 1L Therapy for Hepatocellular Carcinoma

Innovent's Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) Receive the NMPA's Approval as 1L Therapy for Hepatocellular Car...

  • June 29, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.